Loading
A phase 1 trial of ALA-101 run by Arovella Therapeutics Ltd, now recruiting.
Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia. is a phase 1 interventional study registered as NCT07518329 by Arovella Therapeutics Ltd, with 46 participants planned, started 2026-10-19. Conditions recorded: Non Hodgkin Lymphoma (NHL) and Leukaemia. Interventions recorded: ALA-101.
Shares Arovella Therapeutics and the tag pipeline.
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/